AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUROTECH INTERNATIONAL LTD

0.027

-0.003-10.00%

Volume:856.01K

Turnover:23.93K

Market Cap:28.14M

PE:-2.26

High:0.030

Open:0.030

Low:0.027

Close:0.030

Loading ...

Overview Company News Filings

BUZZ-Australia's Neurotech gains as Rett Syndrome drug gets 'orphan' tag from EU

Neurotech's Drug Candidate Receives Orphan Drug Status from European Commission; Shares Rise 3%

MT Newswires Live

Neurotech International Says European Commission Grants NTI164 Orphan Drug Designation

Neurotech International - European Commission Grants Nti164 Orphan Drug Designation for Rett Syndrome

THOMSON REUTERS

Here's Why Neurotech International (ASX:NTI) Must Use Its Cash Wisely

Simply Wall St.

Here's Why We're A Bit Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

Simply Wall St.

BRIEF-Neurotech International Logs HY Loss From Ordinary Activities A$7.445 Mln

BRIEF-Neurotech International Says European Medicines Agency Issued Positive Opinion On Orphan Medicinal Product Designation Application Of NTI164

Neurotech International - Hy Loss From Ordinary Activities a$7.445 Mln

THOMSON REUTERS

Neurotech International - European Medicines Agency Issued Positive Opinion on Orphan Medicinal Product Designation Application of Nti164

THOMSON REUTERS

Neurotech International Signs Cannabis-Based Product Development Deal

MT Newswires Live

BRIEF-Neurotech International Signs Development Agreement For Cannabinoid Therapies

Neurotech International Ltd - Nti Signs Development Agreement for Cannabinoid Therapies

THOMSON REUTERS

Neurotech International - Enters Partnership Agreement With RH Farma Dooel Skopje

THOMSON REUTERS

Is There Now An Opportunity In Neurotech International Limited (ASX:NTI)?

Simply Wall St.

Neurotech Secures Ethics Approval for Study of Cannabis-Based Drug Candidate in Adults; Shares Up 8%

MT Newswires Live

BRIEF-Neurotech International Receives US Orphan Drug Designation In Rett Syndrome

BUZZ-Australia's Neurotech International jumps on FDA orphan tag for Rett Syndrome drug

Neurotech International Ltd - Receives US Orphan Drug Designation in Rett Syndrome

THOMSON REUTERS

ASX Market Update: Index breaks intra-day record | November 25, 2024

The Market Herald

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NTI.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NTI.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTI.AU\",,,,,undefined,":{"symbol":"NTI.AU","market":"AU","secType":"STK","nameCN":"NEUROTECH INTERNATIONAL LTD","latestPrice":0.027,"timestamp":1744870320000,"preClose":0.03,"halted":0,"volume":856013,"delay":0,"nameEN":"NEUROTECH INTERNATIONAL LTD","floatShares":760583617,"shares":1042121921,"eps":-0.011964,"marketStatus":"Closed Easter Monday","change":-0.003,"latestTime":"04-17 16:12:00 AEST","open":0.03,"high":0.03,"low":0.027,"amount":23933,"amplitude":0.1,"askPrice":0.028,"askSize":150000,"bidPrice":0.027,"bidSize":470011,"shortable":3,"etf":0,"ttmEps":-0.011964,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.03,"openAndCloseTimeList":[[1744848000000,1744869600000]],"volumeRatio":2.1236496046998132,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTI.AU\",,,,,undefined,":{"symbol":"NTI.AU","floatShares":760583617,"roa":"-129.79%","roe":"-223.80%","lyrEps":-0.005558,"volumeRatio":2.1236496046998132,"shares":1042121921,"dividePrice":0,"high":0.03,"amplitude":0.1,"preClose":0.03,"low":0.027,"week52Low":0.026,"pbRate":"4.90","psRate":"349.64","week52High":0.1,"institutionHeld":0,"latestPrice":0.027,"committee":0.516138,"eps":-0.011964,"divideRate":0,"volume":856013,"delay":0,"ttmEps":-0.011964,"open":0.03,"prevYearClose":0.055,"prevWeekClose":0.03,"prevMonthClose":0.033,"prevQuarterClose":0.033,"fiveDayClose":0.03,"twentyDayClose":0.036,"sixtyDayClose":0.048},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NTI.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523952287","title":"BUZZ-Australia's Neurotech gains as Rett Syndrome drug gets 'orphan' tag from EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2523952287","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523952287?lang=en_us&edition=fundamental","pubTime":"2025-03-31 12:35","pubTimestamp":1743395723,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurotech gains as Rett Syndrome drug gets 'orphan' tag from EU   ** Shares of Neurotech International NTI.AX rise 6.5% to A$0.033** Stock set for strongest session since March 18, if current gains hold** European Commission gives \"orphan drug\" designation to biopharmaceutical firm's NTI64 drug aimed at treating Rett Syndrome, a neurodevelopmental disorder that affects motor and communication skills** European Commission grants \"orphan drug\" designation to promote medicine development for rare diseases affecting no more than 5 in 10,000 people in the European Union** Co says \"orphan\" status gives it a range of incentives including 10-year market exclusivity, reduced regulatory fees and access to EU research funding** Stock down 40% YTD, including current session's moves  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL6N3QE07B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2523956755","title":"Neurotech's Drug Candidate Receives Orphan Drug Status from European Commission; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2523956755","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523956755?lang=en_us&edition=fundamental","pubTime":"2025-03-31 11:27","pubTimestamp":1743391639,"startTime":"0","endTime":"0","summary":"Neurotech International  has received Orphan Drug Designation from the European Commission for NTI164, its lead drug candidate for Rett Syndrome, a neurodevelopmental disorder, according to a Monday filing with the Australian bourse.The designation grants market exclusivity, reduced regulatory fees, access to research funding, and protocol assistance, the filing said.Shares of the firm rose past 3% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2523378029","title":"Neurotech International Says European Commission Grants NTI164 Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2523378029","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523378029?lang=en_us&edition=fundamental","pubTime":"2025-03-31 09:51","pubTimestamp":1743385917,"startTime":"0","endTime":"0","summary":"March 31 (Reuters) - Neurotech International Ltd ::*EUROPEAN COMMISSION GRANTS NTI164 ORPHAN DRUG DESIGNATION FOR RETT SYNDROME  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 30-MAR-202522:39:26.03 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nRSD3rRfpg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2523180982","title":"Neurotech International -  European Commission Grants Nti164 Orphan Drug Designation for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2523180982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523180982?lang=en_us&edition=fundamental","pubTime":"2025-03-31 06:40","pubTimestamp":1743374453,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250330:nFWN3QC00I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2518881478","title":"Here's Why Neurotech International (ASX:NTI) Must Use Its Cash Wisely","url":"https://stock-news.laohu8.com/highlight/detail?id=2518881478","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518881478?lang=en_us&edition=fundamental","pubTime":"2025-03-09 07:47","pubTimestamp":1741477643,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.So, the natural question for Neurotech International  shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.How Is Neurotech International's Cash Burn Changing Over Time?Since it has a market capitalisation of AU$34m, Neurotech International's AU$9.8m in cash burn equates to about 29% of its m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-neurotech-international-asx-234723303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2517912667","title":"Here's Why We're A Bit Worried About Neurotech International's (ASX:NTI) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2517912667","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517912667?lang=en_us&edition=fundamental","pubTime":"2025-03-05 13:41","pubTimestamp":1741153274,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-nti/neurotech-international-shares/news/heres-why-were-a-bit-worried-about-neurotech-internationals","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2514821051","title":"BRIEF-Neurotech International Logs HY Loss From Ordinary Activities A$7.445 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514821051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514821051?lang=en_us&edition=fundamental","pubTime":"2025-02-27 16:15","pubTimestamp":1740644120,"startTime":"0","endTime":"0","summary":"BRIEF-Neurotech International Logs HY Loss From Ordinary Activities A$7.445 MlnFeb 27 (Reuters) - Neurotech International Ltd NTI.AX:HY LOSS FROM ORDINARY ACTIVITIES A$7.445 MILLIONFurther company coverage: NTI.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI0UR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2514682114","title":"BRIEF-Neurotech International Says European Medicines Agency Issued Positive Opinion On Orphan Medicinal Product Designation Application Of NTI164","url":"https://stock-news.laohu8.com/highlight/detail?id=2514682114","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514682114?lang=en_us&edition=fundamental","pubTime":"2025-02-27 16:12","pubTimestamp":1740643950,"startTime":"0","endTime":"0","summary":"BRIEF-Neurotech International Says European Medicines Agency Issued Positive Opinion On Orphan Medicinal Product Designation Application Of NTI164Feb 27  - Neurotech International Ltd NTI.AX:EUROPEAN MEDICINES AGENCY ISSUED POSITIVE OPINION ON ORPHAN MEDICINAL PRODUCT DESIGNATION APPLICATION OF NTI164Further company coverage: NTI.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1LP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2514825169","title":"Neurotech International - Hy Loss From Ordinary Activities a$7.445 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514825169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514825169?lang=en_us&edition=fundamental","pubTime":"2025-02-27 15:42","pubTimestamp":1740642152,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI0UR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2514819488","title":"Neurotech International - European Medicines Agency Issued Positive Opinion on Orphan Medicinal Product Designation Application of Nti164","url":"https://stock-news.laohu8.com/highlight/detail?id=2514819488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514819488?lang=en_us&edition=fundamental","pubTime":"2025-02-27 10:00","pubTimestamp":1740621640,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1LP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2511502435","title":"Neurotech International Signs Cannabis-Based Product Development Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2511502435","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511502435?lang=en_us&edition=fundamental","pubTime":"2025-02-14 07:48","pubTimestamp":1739490498,"startTime":"0","endTime":"0","summary":"Neurotech International  signed an agreement with RH Farma Dooel Skopje, a subsidiary of European Cannabis Company, to develop cannabinoid therapies, according to a Thursday filing with the Australian bourse.The development aims to create a pharmaceutical-grade broad-spectrum cannabinoid drug product for pediatric neurodevelopmental disorders, the filing said.The agreement involves an initial payment of 25,000 euros, with additional services to be provided over a 12-month term, according to the filing.Neurotech International's shares fell past 2% in recent Friday trade.Price : $0.04, Change: $-0.0010, Percent Change: -2.27%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0426417589.USD","NTI.AU","AUD","LU0994945656.USD","LU2238339852.HKD","LU0426412945.USD","LU1043141123.HKD","BK7007","LU0345774631.USD","BK4125"],"gpt_icon":0},{"id":"2511559889","title":"BRIEF-Neurotech International Signs Development Agreement For Cannabinoid Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2511559889","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511559889?lang=en_us&edition=fundamental","pubTime":"2025-02-13 09:42","pubTimestamp":1739410942,"startTime":"0","endTime":"0","summary":"BRIEF-Neurotech International Signs Development Agreement For Cannabinoid TherapiesFeb 13  - Neurotech International Ltd NTI.AX:NEUROTECH INTERNATIONAL LTD - NTI SIGNS DEVELOPMENT AGREEMENT FOR CANNABINOID THERAPIESNEUROTECH INTERNATIONAL - ENTERS PARTNERSHIP AGREEMENT WITH RH FARMA DOOEL SKOPJEFurther company coverage: NTI.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nFWN3P321H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2511531513","title":"Neurotech International Ltd - Nti Signs Development Agreement for Cannabinoid Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2511531513","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511531513?lang=en_us&edition=fundamental","pubTime":"2025-02-13 06:59","pubTimestamp":1739401171,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P321H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2511315155","title":"Neurotech International - Enters Partnership Agreement With RH Farma Dooel Skopje","url":"https://stock-news.laohu8.com/highlight/detail?id=2511315155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511315155?lang=en_us&edition=fundamental","pubTime":"2025-02-13 06:59","pubTimestamp":1739401171,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P321H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2489621832","title":"Is There Now An Opportunity In Neurotech International Limited (ASX:NTI)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489621832","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489621832?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:44","pubTimestamp":1733521463,"startTime":"0","endTime":"0","summary":"Neurotech International Limited , is not the largest company out there, but it saw a decent share price growth of 15% on the ASX over the last few months. Shareholders may appreciate the recent price jump, but the company still has a way to go before reaching its yearly highs again. As a small cap stock, hardly covered by any analysts, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value. Is there still an opportunity here to buy?Let’s examine Neurotech International’s valuation and outlook in more detail to determine if there’s still a bargain opportunity.Check out our latest analysis for Neurotech International","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qrnhoA9Y9l_fYJBd0ck5WA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/983f2bdfe32b19227b1d118c45bf4f09","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qrnhoA9Y9l_fYJBd0ck5WA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/983f2bdfe32b19227b1d118c45bf4f09"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/now-opportunity-neurotech-international-limited-214423131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2486016380","title":"Neurotech Secures Ethics Approval for Study of Cannabis-Based Drug Candidate in Adults; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486016380","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486016380?lang=en_us&edition=fundamental","pubTime":"2024-11-26 11:42","pubTimestamp":1732592535,"startTime":"0","endTime":"0","summary":"Neurotech International (ASX:NTI) secured approval from the Human Research Ethics Committee to conduct a pharmacokinetic study of cannabis-based drug candidate NTI164 in healthy human adults at the CM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","LU1043141123.HKD","XKO.AU","XAO.AU","BK4125","LU2238339852.HKD","LU0345774631.USD","LU0426412945.USD","AUD","LU0994945656.USD","BK7007","LU0426417589.USD","NTI.AU"],"gpt_icon":0},{"id":"2486099391","title":"BRIEF-Neurotech International Receives US Orphan Drug Designation In Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2486099391","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486099391?lang=en_us&edition=fundamental","pubTime":"2024-11-26 09:22","pubTimestamp":1732584141,"startTime":"0","endTime":"0","summary":"Nov 26 (Reuters) - Neurotech International Ltd   :   * RECEIVES US ORPHAN DRUG DESIGNATION IN RETT SYNDROMEFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2486093669","title":"BUZZ-Australia's Neurotech International jumps on FDA orphan tag for Rett Syndrome drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2486093669","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486093669?lang=en_us&edition=fundamental","pubTime":"2024-11-26 08:30","pubTimestamp":1732581007,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurotech International jumps on FDA orphan tag for Rett Syndrome drug** Shares of Neurotech International NTI.AX rise as much as 10.6% to A$0.073, posting their biggest intraday percentage gain since Aug. 14** Stock hits its highest level since Sept. 9** Biopharmaceutical co says the U.S. Food and Drug Administration granted the orphan drug status to its NTI164 drug, aimed at treating Rett Syndrome ** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.** About 1.6 mln shares change hands, compared with the 30-day average volume of around 601,000** Stock up 1.5% YTD, including session's move  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nL3N3MX01J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2486766061","title":"Neurotech International Ltd - Receives US Orphan Drug Designation in Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2486766061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486766061?lang=en_us&edition=fundamental","pubTime":"2024-11-26 06:46","pubTimestamp":1732574763,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nFWN3MW0RG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2486740944","title":"ASX Market Update: Index breaks intra-day record | November 25, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2486740944","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486740944?lang=en_us&edition=fundamental","pubTime":"2024-11-25 10:52","pubTimestamp":1732503120,"startTime":"0","endTime":"0","summary":"The ASX200 has been up 0.7% after hitting a new all time intra-day high of 8,462 points. The bourse continues to trade close to record levels and analyst chatter is swirling around whether it will be a record close.The Real Estate sector has been the best performer, up 2.2%, followed by Discretionary, up 1.5%, and Health Care, up 1.45%. Financials has been the only sector to lose ground, down around a fifth of a percent.Australia’s biggest listed company Commonwealth Bank  has been down 0.25% after hitting a fresh all time high of $160.27 this morning. The company continues to rise, despite trading on a price to earnings ratio of 28.Novonix  has been up 23% after inking a binding offtake agreement with PowerCo SE. The deal sees Novonix supply a minimum of 32,000 tonnes of high-performance synthetic graphite to PowerCo over a five-year period, starting in 2027.Neurotech has been down 4.35% after launching a baseline data study as part of its response to an FDA fast track rejection. The ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-index-breaks-intra-day-record-november-25-2024-2024-11-25/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK4157","CBA.AU","BK7007","BK4218","BK7135","NTI.AU","NVX","BK7084","BK4181","PK","NVX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NTI.AU\",params:#limit:5,,,undefined,":[{"date":"2023-10-27","symbol":"NTI.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1698361200000,"name":null,"time":"","dateTimestamp":1698325200000,"actualEps":null},{"date":"2023-07-26","symbol":"NTI.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690329600000,"name":null,"time":"","dateTimestamp":1690293600000,"actualEps":null},{"market":"AU","date":"2023-04-27","symbol":"NTI.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1682517600000,"reportTimeType":"","actualEps":null},{"date":"2023-01-30","symbol":"NTI.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1675033200000,"name":null,"time":"","dateTimestamp":1674997200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NTI.AU\",market:\"AU\",,,undefined,":[]}}